NNVC NanoViricides Inc
Company Analysis
Latest News
NanoViricides Inc Q2 2026 Earnings Preview: What Analysts Expect on October 05, 2026
NanoViricides is expected to report a consensus EPS of -$0.11 on zero revenue for the quarter ending June 30, 2026, with the current $1.30 stock price trading...
🟢 NanoViricides is trading 7.9% up in pre-market with no October 2 company-specific catalyst identified
NanoViricides is trading 7.9% higher in pre-market at $1.36, compared with the October 1 close of $1.26; no new company-specific announcement dated October 2...
NanoViricides Starts Phase II Ebola Trial, Says More Funding Is Needed
NanoViricides, Inc. announced that patients have been enrolled and dosed in its Phase II clinical trial of NV-387 oral gummies for Ebola in the Democratic...
🟢 NanoViricides is trading 7.7% up in pre-market with no clear catalyst identified
NanoViricides is trading at $1.40, up +7.69% in pre-market, with no clear catalyst identified for the September 30 move. - The company’s fiscal 2026 annual...
🔴 NanoViricides is trading 10.3% down
NanoViricides is trading 10.3% down at $1.34 on September 29, 2026, with no clearly identified catalyst for the intraday decline. - The company announced...
🔴 NanoViricides is trading 6% down
NanoViricides is trading 6.00% lower at $1.41, with no clear company-specific announcement explaining the September 29 decline. - The company announced on...
🟢 NanoViricides is trading 6% up in pre-market after Phase II NV-387 Ebola trial dosing began
NanoViricides is trading 6.02% higher in pre-market at $1.59 after enrollment and dosing began in its Phase II oral NV-387 Ebola trial. - It closed at $1.50 on...
🟢 NanoViricides is trading 5% up today after Phase II Ebola trial dosing began
NanoViricides is trading 5.21% higher at $1.51 after announcing that enrollment and dosing began in its Phase II oral NV-387 Ebola trial. - The company...
🔴 NanoViricides is trading 5.4% down today amid biotech-sector weakness
NanoViricides is trading at $1.43 (-5.40%) as biotechnology-sector weakness weighs on shares. - NanoViricides is declining despite September 23 news that...
🟢 NanoViricides is trading 6.54% up today after Phase II MPox trial enrollment began
NanoViricides is trading 6.54% up at $1.63; on September 23, 2026, it announced that enrollment of the first patients began in its Phase II NV-387 trial for...
🟢 NanoViricides is trading 8.52% up in pre-market
NanoViricides is trading 8.52% higher at $1.66 in pre-market, rebounding from its September 22 close of $1.53; no immediate catalyst has been identified. - No...
🟢 NanoViricides is trading 6.19% up in after-hours trading; catalyst unclear
NanoViricides is trading 6.19% higher at $1.63 after rising following a 9.17% regular-session decline on September 22, 2026; the cause remains unclear. - No...
🔴 NanoViricides is trading 6.51% down today
NanoViricides is trading 6.51% lower at $1.58, with no clearly reported company-specific negative catalyst identified for September 22, 2026. - The latest...
🟢 NanoViricides is trading 13.79% up today on Phase II Ebola trial interest
NanoViricides is trading 13.79% up at $1.62 as investor interest builds around its Phase II NV-387 oral-gummy Ebola trial. - The study is scheduled to begin...
🟢 NanoViricides is trading 6.33% up today on investor interest in Phase II Ebola trial
NanoViricides is trading 6.33% up at $1.56 as investor interest continues around its Phase II NV-387 oral-gummy Ebola trial. - The trial is scheduled to begin...
🟢 NanoViricides is trading 7% up in pre-market ahead of Phase II Ebola trial start
NanoViricides is trading at $1.52, up 7.04% now, extending gains after its September 15 announcement that the Phase II NV-387 oral-gummy Ebola trial is...
🟢 NanoViricides is trading 5% up today ahead of Phase II Ebola trial start
NanoViricides is trading 5% up at $1.47 after investors continued reacting to the company’s September 15 announcement that its Phase II NV-387 oral-gummy Ebola...
🟢 NanoViricides Inc is trading 5.00% up in pre-market
NNVC is trading at $1.47, up 5.00% in pre-market.
🟢 NanoViricides is trading 5.6% up in after-hours trading ahead of Phase II Ebola trial next week
NanoViricides is trading 5.6% up at $1.50 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week in Ituri province,...
🟢 NanoViricides is trading 15.01% up today ahead of Phase II NV-387 Ebola trial next week
NanoViricides is trading 15.01% up now at $1.37 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week. - The trial...